Effects of rolipram and diazepam on the adaptive changes induced by morphine withdrawal in the hypothalamic paraventricular nucleus

European Journal of Pharmacology

Volumn 620, Issue 1-3, 2009, Pages 1-8

  Núñez, Cristina ^a   González Cuello, Ana ^a   Sánchez, Lorenzo ^a   Vargas, M Luisa ^a   Milanés, M Victoria ^a   Laorden, M Luisa ^a  

^a UNIVERSITY OF MURCIA   (Spain)

Author keywords

c Fos; Cyclic AMP; Cyclic GMP; Diazepam; Morphine withdrawal; Noradrenaline turnover; PVN; Rolipram

Indexed keywords

CYCLIC AMP; CYCLIC GMP; DIAZEPAM; MORPHINE; NALOXONE; NORADRENALIN; PROTEIN C FOS; ROLIPRAM;

ADAPTATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CATECHOLAMINE METABOLISM; CATECHOLAMINERGIC SYSTEM; CONTROLLED STUDY; DETOXIFICATION; DRUG EFFICACY; DRUG MECHANISM; HYPOTHALAMUS PERIVENTRICULAR NUCLEUS; IMMUNOHISTOCHEMISTRY; MALE; MORPHINE ADDICTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; UPREGULATION; WITHDRAWAL SYNDROME;

ADAPTATION, PHYSIOLOGICAL; ANIMALS; CYCLIC AMP; CYCLIC GMP; DIAZEPAM; GENE EXPRESSION REGULATION; MALE; MORPHINE; NEUROSECRETORY SYSTEMS; NOREPINEPHRINE; PARAVENTRICULAR HYPOTHALAMIC NUCLEUS; PHOSPHODIESTERASE INHIBITORS; PITUITARY GLAND; PROTO-ONCOGENE PROTEINS C-FOS; RATS; RATS, SPRAGUE-DAWLEY; ROLIPRAM; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 70349139213     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.08.002     Document Type: Article

References (62)

1. Alexander S.P.H., Mathie E., and Peters J.A. Guide to receptors and channels (GRAC), 3rd edn (2008 revision). Br. J. Pharmacol. 150 Suppl. 1 (2008) S1-S168
2. Almela P., Milanés M.V., and Laorden M.L. Activation of ERK signalling pathway contribuyes to the adaptive changes in rat hearts during naloxone-induced morphine withdrawal. Br. J. Pharmacol. 151 (2007) 787-797
3. Artigas F., Sarrias M.J., Adell A., and Gelpí E. Quantification of total MHPG in the rat brain using a non enzymatic hydrolysis procedure. Effects of drugs. Life Sci. 39 (1986) 1571-1578
4. Atkins C.M., Selcher J.C., Petraitis J.J., Trzaskos J.M., and Sweatt J.D. The MAPK cascade is required for mammalian associative learning. Nat. Neurosci. 1 (1998) 602-609
5. Beavo J.A. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol. Rev. 75 (1995) 725-748
6. Benavides M., Laorden M.L., and Milanés M.V. Regulation of tyrosine hydroxylase levels and activity and Fos expression during opioid withdrawal in the hypothalamic PNV and medulla oblongata catecholaminergic cell groups innervating the PVN. Eur. J. Neurosci. 17 (2003) 103-112
7. Bender A.T., and Beavo J.A. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol. Rev. 58 (2006) 488-520
8. B receptor agonist baclofen. Life Sci. 70 (2001) 395-401
9. Blendy J.A., and Maldonado R. Genetic analysis of drug addiction: the role of cAMP response element binding proteins. J. Mol. Med. 76 (1998) 104-110
10. Burton C.K., Ho I.K., and Hoskins B. Effect of cyclo (Leu-Gly) on cyclic GMP-phosphodiesterase activity changes associated with development of tolerance to morphine-induced actinociception, catalepsy, respiratory depression and mydriasis. J. Pharmacol. Exp. Ther. 258 (1991) 871-876
11. Childers S.R. Opioid receptor-coupled second messengers systems. Life Sci. 48 (1991) 1991-2003
12. Chrivia J.C., Kwok R.P., Lamb N., Hagiwara M., Montminy M.R., and Goodman R.H. Phosphorylated CREB finds specifically to the nuclear protein CBP. Nature 365 (1993) 855-859
13. Cherry J.A., and Davis R.L. Cyclic AMP phosphodiesterase are localizad in regions of the mouse brain associated with reinforcement, movement and affect. J. Comp. Neurol. 407 (1999) 287-301
14. Cleck J.N., and Blendy J.A. Making a bad thing worse: adverse effects of stress on drug addiction. J. Clin. Invest. 118 (2008) 454-461
15. Collado M.C., Beleta J., Martínez E., Miralpeix M., Doménech T., Palacios J.M., and Hernández J. Functional and biochemical evidence for diazepam as a cyclic nucleotide phosphodiesterase type 4 inhibitor. Br. J. Pharmacol. 123 (1998) 1047-1054
16. Collins S.P., and Uhler M.D. Cyclic AMP- and cyclic GMP-dependent protein kinases differ in their regulation of cyclic AMP response element-dependent gene transcription. J. Biol. Chem. 274 (1999) 8391-8404
17. Conti M., Richter W., Mehats C., Livera G., Park J.Y., and Jin C. Cyclic AMP-specific PDE4 phosphodiesterases as critical components of cyclic AMP signalling. J. Biol. Chem. 278 (2003) 5493-5496
18. Curran E., Akil H., and Watson S. Psychomotor stimulant- and opiate-induced c-fos mRNA expression patterns in the rat forebrain: comparisons between acute drug treatment and a drug challenge in sensitised animals. Neurochem. Res. 21 (1996) 1425-1435
19. + 2/calmodulin-dependent protein kinase IV. Role in transcription regulation. J. Biol. Chem. 22 (1994) 15520-15527
20. Fuertes G., Laorden M.L., and Milanés M.V. Noradrenergic and dopaminergic activity in the hypothalamic paraventricular nucleus after naloxone-induced morphine withdrawal. Neuroendocrinology 71 (2000) 60-67
21. Goeders N.E. Stress and cocaine addiciton. J. Pharmacol. Exp. Ther. 301 (2002) 785-789
22. González-Cuello A., Sánchez L., Hernández J., Castells M.T., Milanés M.V., and Laorden M.L. Phosphodiesterase 4 inhibitors, rolipram and diazepam block the adaptive changes observed during morphine withdrawal in the heart. Eur. J. Pharmacol. 570 (2007) 1-9
23. Hamdy M.M., Mamiya T., Noda Y., Sayed M., Assi A.A., Gomaa A., Yamada K., and Nabeshima T. A selective phosphodiesterase IV inhibitor, rolipram blocks body withdrawal behavioural manifestations, and c-Fos protein expression in morphine dependent mice. Behav. Brain. Res. 118 (2001) 85-93
24. Houslay M.D. PDE4-cAMP-specific phosphodiesterase. Prog. Nuclei Acid Res. Mol. Biol. 69 (2001) 249-315
25. Houslay M.D., and Adams D.R. PDE4 cAMP phosphodiesterase: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization. Biochemistry 370 (2003) 1-18
26. Itoh A., Noda Y., Mamiya T., Hasegawa T., and Nabeshima T. A therapeutic strategy to prevent morphine dependence and tolerance by co-administration of cAMP-related reagents with morphine. Methods Find. Exp. Clin. Pharmacol. 20 (1998) 619-625
27. Itoh A., Shiotani T., Nakayama S., Mamiya T., Hasegawa T., Noda Y., and Nabeshima T. Attenuation of the development of morphine dependence/tolerance by nefiracetam: involvement of adenosine 3′:5′-cyclic monophosphate system. Beh. Brain Res. 115 (2000) 65-74
28. Kemmling A.K., Rubio M.C., and Balerio G.M. Baclofen prevents morphine withdrawal irrespective of seasonal variation. Behav. Pharmacol. 13 (2002) 87-92
29. Kimura A., Tokumura M., Itoh T., Inoue O., and Abe K. Lack of cyclic AMP-specific phosphodiesterase 4 activation during naloxone-precipitated morphine withdrawal in rats. Neurosci. Letters 404 (2006) 107-111
30. Koob G.F., and Le Moal M. Neurobiological mechanisms for opponent motivational processes in addiction. Phil Trans. R. Soc. B. 363 (2008) 313-3123
31. Laorden M.L., Castells M.T., Martínez M.D., Martínez P.J., and Milanés M.V. Activation of c-fos expression in hypothalamic nuclei by mu- and kappa-receptor agonists. Correlation with catecholaminergic activity in the hypothalamic paraventricular nucleus. Endocrinology 141 (2000) 1366-1376
32. Laorden M.L., Castells M.T., and Milanés M.V. Effects of morphine and morphine withdrawal on brainstem neurons innervating hypothalamic nuclei that control the pituitary-adrenocortical axis in rats. Br. J. Pharmacol. 136 (2002) 67-75
33. Laorden M.L., Núñez C., Almela P., and Milanés M.V. Morphine withdrawal-induced c-fos expression in the hypothalamic paraventricular nucleus is dependent on the activation of catecholaminergic neurones. J. Neurochem. 83 (2002) 132-140
34. Liu J.G., and Anand K.J. Protein kinase modulates the cellular adaptations associated with opioid tolerance and dependence. Brain Res. Brain Res. Rev. 38 (2001) 1-19
35. Lookingland K.J., Ireland L.M., Gunnet J.W., Manzanares J., Tian Y., and Moore K.E. 3-Methoxy-4-hydroxyphenylethyleneglycol concentrations in discrete hypothalamic nuclei reflect the activity of noradrenergic neurons. Brain Res. 559 (1991) 82-88
36. Lucas K.A., Pitari G.M., Kazerounian S., Ruiz-Stewart I., Park J., Schulz S., Chepenik K.P., and Waldman S.A. Guanyl cyclases and signalling by cyclic GMP. Pharmacol. Rev. 52 (2000) 375-413
37. Maldonado R., Mico J.A., Valverde O., Saavedra M.C., Leonsegui I., and Gibert-Rahola J. Influence of different benzodiazepines on the experimental morphine abstinence syndrome. Psychopharmacology 105 (1991) 197-203
38. Mamiya T., Noda Y., Ren X., Hamdy M., Furukawa S., Kameyama T., Yamada K., and Nabeshima T. Involvement of cyclic AMP systems in morphine physical dependence in mice: prevention of development of morphine dependence by rolipram a phosphodiesterase 4 inhibitor. Br. J. Pharmacol. 132 (2001) 1111-1117
39. Mehats C., Andersen C.B., Filopanti M., Jin S.L., and Conti M. Cyclic nucleotide phopsphodiesterases and their role in endocrine cell signalling. Trends Endocri. Metab. 13 (2002) 29-35
40. Milanés M.V., Laorden M.L., Chapleur-Chateau M., and Burlet A. Alterations in corticotropin-releasing factor and vasopressin content in rat brain during morphine withdrawal: correlation with hypothalamic noradrenergic activity and pituitary-adrenal response. J. Pharmacol. Exp. Ther. 285 (1998) 700-706
41. Mirzaii-Dizgah I., Karimian S.M., Hajimashhadi Z., Riahi E., and Ghasemi T. Attenuation of morphine withdrawal signs by muscimol in the locus coeruleus of rats. Behav. Pharmacol. 19 (2008) 171-175
42. Monje P., Hernández-Losa J., Lyons R.J., Castellone M.D., and Gutkind J.S. Regulation of the transcriptional activity of c-Fos by ERK. A novel role for the prolyl isomerase PIN1. J. Biol. Chem. 280 (2005) 35081-35084
43. Morgan J.I., and Curran T. Stimulus transcription coupling in the nervous system: involvement of the inducible proto-oncogenes fos and jun. Ann. Rev. Neurosci. 14 (1991) 421-451
44. Nestler E.J. Molecular mechanism of drug addiction. J. Neurosci. 278 (1992) 58-63
45. Núñez C., Földes A., Laorden M.L., Milanés M.V., and Kovács K.J. Activation of stress-related hypothalamic neuropeptide gene expression during morphine withdrawal. J. Neurochem. 101 (2007) 1060-1071
46. Núñez C., Castells M.T., Laorden M.L., and Milanés M.V. Regulation of extracellular signal-regulated kinases (ERKs) by naloxone-induced morphine withdrawal in the brain stress system. Naunyn Schmiedebergs Arch. Pharmacol. 378 (2008) 407-420
47. Palkovits M. Isolated removal of hypothalamic or other brain nuclei of the rat. Brain Res. 59 (1973) 449-450
48. Palkovits M., and Brownstein M.J. Maps and guide to microdissection of the rat brain (1988), New York, Elsevier
49. Paxinos G., and Watson C. The rat brain in stereotaxic coordinates. fourth ed. (1998), Academic Press, San Diego
50. Perez Torres S., Miró X., Palacios J.M., Cortes R., Puigdomenech P., and Mengod G. Phosphodiesterase type 4 isoenzyme expression in human brain examined by in situ hibridization histochemistry and (3 h) rolipram binding autoradiography. Comparison with monkey and rat brain. J. Chem. Neuroanat. 20 (2000) 349-374
51. B receptor agonist in the locus coeruleus of rats. Behav. Brain Res. 196 (2009) 11-14
52. Selley D.E., Nestler E.J., Breivogel C.S., and Childers S.R. Opioid receptor-coupled G-proteins in rat locus coeruleus membranes: decrease in activity after chronic morphine treatment. Brain Res. 746 (1997) 10-18
53. Sheng M., and Greenberg M.E. The regulation and function of c-fos and other immediate early genes in the nervous system. Neuron 4 (1990) 477-485
54. Sheu M.J., Sribanditmongkol P., Santosa D.N., and Tejwani G.A. Inhibition of morphine tolerance and dependence by diazepam and its relation to cyclic AMP levels in discrete rat brain regions and spinal cord. Brain Res. 675 (1995) 31-37
55. Sonnenburg J.A., and Beavo J.A. Cyclic GMP and regulation of cyclic nucleotide hydrolysis. Adv. Pharmacol. 26 (1994) 87-114
56. Sullivan M.E., Hall S.R., Milne B., and Jhamandas K. Suppression of acute and chronic opioid withdrawal by a selective soluble guanylyl cyclase inhibitor. Brain Res. 859 (2000) 45-56
57. Suzuki T., Tsuda M., Narita M., Funada M., Mizoguchi H., and Misawa M. Diazepam pretreatment suppresses morphine withdrawal signs in the mouse. Life Sci. 58 (1995) 349-357
58. Swanson L.W., and Simmons D.M. Differential steroid hormone and neural influences on peptide mRNA levels in CRH cells of the paraventricular nucleus: a hybridization histochemical study in the rat. J. Comp. Neurol. 285 (1989) 413-435
59. Tokuyama S., Feng Y., Wakabayashi H., and Ho I.K. Possible involvement of proteinkinases in physical dependence on opioids: studies using protein kinase inhibitors, H-7 and H-8. Eur. J. Pharmacol. 284 (1995) 101-107
60. Wegener A., and Kunmer W. Sympathetic noradrenergic fibbers as the source of immunoreactivity alpha-neoendorphin and dynorphin in the guinea-pig heart. Acta Anat. 151 (1994) 112-119
61. Williams J.T., Christie J., and Manzoni O. Cellular and synaptic adaptations mediating opioide dependence. Phisiol. Rev. 81 (2001) 299-343
62. Zarrindast M.R., and Mousa-Ahmadi E. Effects of GABAergic system on naloxone-induced jumping in morphine-dependent mice. Eur. J. Pharmacol. 381 (1999) 129-133